January 2020 in “Química Nova” The PW91 method is best for calculating the basic physical and chemical properties of Finasteride, a drug used for prostate issues and hair loss.
64 citations
,
March 2008 in “Neuropsychopharmacology”
June 2026 in “Oriental Journal Of Chemistry” Steroid 12 shows promise as a targeted treatment for prostate cancer by selectively reducing cell growth and increasing cell death.
Marine sponges from Tabuhan Island can inhibit enzymes linked to Alzheimer's and hair loss.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
1 citations
,
July 2013 in “Clinical Drug Investigation”
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
38 citations
,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.
6 citations
,
November 2022 in “BMC Urology” Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
2 citations
,
May 2023 in “Al Mustansiriyah Journal of Pharmaceutical Sciences” Pterostilbene significantly reduces prostate enlargement and has strong antioxidant effects.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
1 citations
,
January 2004 in “Medicina de Familia SEMERGEN” Finasteride may help prevent prostate cancer.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
February 2023 in “riUfes (Universidade Federal do Espírito Santo)” High testosterone affects blood vessel function, with estrogen playing a key role in maintaining heart health.
Neurosteroids help control dopamine responses in the brain.
October 2009 in “Nature Reviews Urology”
January 2024 in “Reproductive toxicology” Hesperidin helps protect against testicular damage caused by finasteride.
9 citations
,
August 2000 in “Journal of Periodontal Research” Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.
January 2018 in “International Journal of Medical Research and Health Sciences” Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” Pueraria mirifica extract may help treat benign prostatic hyperplasia.
28 citations
,
February 1999 in “Archives of Dermatological Research” Finasteride potentially treats hair loss by reducing DHT production.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.